Glucuronidation of active tamoxifen metabolites by the human UDP glucuronosyltransferases

Drug Metabolism and Disposition

Volumn 35, Issue 11, 2007, Pages 2006-2014

  Sun, Dongxiao ^a   Sharma, Arun K ^a   Dellinger, Ryan W ^a   Blevins Primeau, Andrea S ^a   Balliet, Renee M ^a   Chen, Gang ^a   Boyiri, Telih ^a   Amin, Shantu ^a   Lazarus, Philip ^a  

^a PENN STATE COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 HYDROXYTAMOXIFEN; DRUG METABOLITE; ENDOXIFEN; GLUCURONOSYLTRANSFERASE; GLUCURONOSYLTRANSFERASE 1A10; GLUCURONOSYLTRANSFERASE 1A7; GLUCURONOSYLTRANSFERASE 2B7; TAMOXIFEN; UNCLASSIFIED DRUG;

ARTICLE; BINDING AFFINITY; CONTROLLED STUDY; DRUG BINDING; DRUG CLEARANCE; DRUG GLUCURONIDATION; DRUG METABOLISM; DRUG SYNTHESIS; ENZYME ACTIVITY; HUMAN; HUMAN CELL; HUMAN TISSUE; LIVER MICROSOME; PRIORITY JOURNAL;

CATALYSIS; CELL LINE; GLUCURONIDES; GLUCURONOSYLTRANSFERASE; GLYCOSYLATION; HUMANS; KINETICS; MASS SPECTROMETRY; MICROSOMES, LIVER; MOLECULAR STRUCTURE; SELECTIVE ESTROGEN RECEPTOR MODULATORS; STEREOISOMERISM; TAMOXIFEN; TRANSFECTION;

EID: 34748901348     PISSN: 00909556     EISSN: 1521009X     Source Type: Journal    
DOI: 10.1124/dmd.107.017145     Document Type: Article

References (39)

1. Babu SR, Lakshmi VM, Hsu FF, Zenser TV, and Davis BB (1992) Role of N-glucuronidation in benzidine-induced bladder cancer in dog. Carcinogenesis 13:1235-1240.
2. Bergman L, Beelen ML, Gallee MP, Hollema H, Benraadt J, and van Leeuwen FE (2000) Risk and prognosis of endometrial cancer after tamoxifen for breast cancer. Comprehensive Cancer Centres' ALERT Group. Assessment of liver and endometrial cancer risk following tamoxifen. Lancet 356:881-887.
3. Burke PJ and Koch TH (2004) Design, synthesis, and biological evaluation of doxorubicin-formaldehyde conjugates targeted to breast cancer cells. J Med Chem 47:1193-1206.
4. Chowdhury S and Ellis P (2005) Extended adjuvant endocrine therapy of early breast cancer. Curr Med Res Opin 21:1985-1995.
5. Coughtrie MW, Burchell B, and Bend JR (1986) A general assay for UDPglucuronosyltransferase activity using polar amino-cyano stationary phase HPLC and UDP[U-14C]glucuronic acid. Anal Biochem 159:198-205.
6. Cuzick J, Powles T, Veronesi U, Forbes J, Edwards R, Ashley S, and Boyle P (2003) Overview of the main outcomes in breast-cancer prevention trials. Lancet 361:296-300.
7. Dellinger RW, Chen G, Blevins-Primeau AS, Krzeminski J, Amin S, and Lazarus P (2007) Glucuronidation of PhIP and N-OH-PhIP by UDP- glucuronosyltransferase 1A10. Carcinogenesis, in press.
8. 139lys isoform. Drug Metab Dispos 34:943-949.
9. [EBCTCG] Early Breast Cancer Trialists' Collaborative Group (1998) Tamoxifen for early breast cancer: an overview of the randomised trials. Lancet 351:1451-1467.
10. Fang JL, Beland FA, Doerge DR, Wiener D, Guillemette C, Marques MM, and Lazarus P (2002) Characterization of benzo(a)pyrene-trans-7,8-dihydrodiol glucuronidation by human tissue microsomes and overexpressed UDP-glucuronosyltransferase enzymes. Cancer Res 62:1978-1986.
11. Fisher B, Costantino JP, Redmond CK, Fisher ER, Wickerham DL, and Cronin WM (1994) Endometrial cancer in tamoxifen-treated breast cancer patients: findings from the National Surgical Adjuvant Breast and Bowel Project (NSABP) B-14. J Natl Cancer Inst 86:527-537.
12. Fisher B, Costantino JP, Wickerham DL, Redmond CK, Kavanah M, Cronin WM, Vogel V, Robidoux A, Dimitrov N, Atkins J, et al. (1998) Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J Natl Cancer Inst 90:1371-1388.
13. Green MD and Tephly TR (1998) Glucuronidation of amine substrates by purified and expressed UDP-glucuronosyltransferase proteins. Drug Metab Dispos 26:860-867.
14. Howell A, Howell SJ, and Evans DG (2003) New approaches to the endocrine prevention and treatment of breast cancer. Cancer Chemother Pharmacol 52 (Suppl 1):S39-S44.
15. Jordan VC, Collins MM, Rowsby L, and Prestwich G (1977) A monohydroxylated metabolite of tamoxifen with potent antioestrogenic activity. J Endocrinol 75:305-316.
16. Kaku T, Ogura K, Nishiyama T, Ohnuma T, Muro K, and Hiratsuka A (2004) Quaternary ammonium-linked glucuronidation of tamoxifen by human liver microsomes and UDP-glucuronosyltransferase 1A4. Biochem Pharmacol 67:2093-2102.
17. Kitagawa M, Ravindernath A, Suzuki N, Rieger R, Terashima I, Umemoto A, and Shibutani S (2000) Identification of tamoxifen-DNA adducts induced by alpha-acetoxy-N-desmethyltamoxifen. Chem Res Toxicol 13:761-769.
18. Lepine J, Bernard O, Plante M, Tetu B, Pelletier G, Labrie F, Belanger A, and Guillemette C (2004) Specificity and regioselectivity of the conjugation of estradiol, estrone, and their catecholestrogen and methoxyestrogen metabolites by human uridine diphosphoglucuronosyltransferases expressed in endometrium. J Clin Endocrinol Metab 89:5222-5232.
19. Lien EA, Solheim E, Lea OA, Lundgren S, Kvinnsland S, and Ueland PM (1989) Distribution of 4-hydroxy-N-desmethyltamoxifen and other tamoxifen metabolites in human biological fluids during tamoxifen treatment. Cancer Res 49:2175-2183.
20. Lim YC, Desta Z, Flockhart DA, and Skaar TC (2005) Endoxifen (4-hydroxy-N-desmethyltamoxifen) has anti-estrogenic effects in breast cancer cells with potency similar to 4-hydroxytamoxifen. Cancer Chemother Pharmacol 55:471-478.
21. McDonald CC and Stewart HJ (1991) Fatal myocardial infarction in the Scottish adjuvant tamoxifen trial. The Scottish Breast Cancer Committee. BMJ 303:435-437.
22. Meier CR and Jick H (1998) Tamoxifen and risk of idiopathic venous thromboembolism. Br J Clin Pharmacol 45:608-612.
23. Murphy CS, Langan-Fahey SM, McCague R, and Jordan VC (1990) Structure-function relationships of hydroxylated metabolites of tamoxifen that control the proliferation of estrogen-responsive T47D breast cancer cells in vitro. Mol Pharmacol 38:737-743.
24. Nechushtan H and Peretz T (2002) Tamoxifen and breast cancer. Harefuah 141:718-720, 761, 760.
25. Nishiyama T, Ogura K, Nakano H, Ohnuma T, Kaku T, Hiratsuka A, Muro K, and Watabe T (2002) Reverse geometrical selectivity in glucuronidation and sulfation of cis- and trans-4-hydroxytamoxifens by human liver UDP-glucuronosyltransferases and sulfotransferases. Biochem Pharmacol 63:1817-1830.
26. Nowell SA, Ahn J, Rae JM, Scheys JO, Trovato A, Sweeney C, MacLeod SL, Kadlubar FF, and Ambrosone CB (2005) Association of genetic variation in tamoxifen-metabolizing enzymes with overall survival and recurrence of disease in breast cancer patients. Breast Cancer Res Treat 91:249-258.
27. Ogawa K, Matsushita Y, Yamawaki I, Kaneda M, Shibata J, Toko T, and Asao T (1991) Synthesis and antiestrogenic activity of the compounds related to the metabolites of (E)-4-[1-[4-[2-(dimethylamino)ethoxy]phenyl]-2-(4- isopropylphenyl)-1-butenyl]phenyl monophosphate (TAT-59) [corrected]. Chem Pharm Bull 39:911-916.
28. Ogura K, Ishikawa Y, Kaku T, Nishiyama T, Ohnuma T, Muro K, and Hiratsuka A (2006) Quaternary ammonium-linked glucuronidation of trans-4- hydroxytamoxifen, an active metabolite of tamoxifen, by human liver microsomes and UDP-glucuronosyltransferase 1A4. Biochem Pharmacol 71:1358-1369.
29. Osborne CK (1998) Tamoxifen in the treatment of breast cancer. N Engl J Med 339:1609-1618.
30. Poon GK, Chui YC, McCague R, Llnning PE, Feng R, Rowlands MG, and Jarman M (1993) Analysis of phase I and phase II metabolites of tamoxifen in breast cancer patients. Drug Metab Dispos 21:1119-1124.
31. Ren Q, Murphy SE, Dannenberg AJ, Park JY, Tephly TR, and Lazarus P (1999) Glucuronidation of the lung carcinogen 4-(methylnitrosamino)-1-(3-pyridyl)-1- butanol (NNAL) by rat UDP-glucuronosyltransferase 2B1. Drug Metab Dispos 27:1010-1016.
32. Ren Q, Murphy SE, Zheng Z, and Lazarus P (2000) O-Glucuronidation of the lung carcinogen 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanol (NNAL) by human UDP-glucuronosyltransferases 2B7 and 1A9. Drug Metab Dispos 28:1352-1360.
33. Robertson DW, Katzenellenbogen JA, Long DJ, Rorke EA, and Katzenellenbogen BS (1982) Tamoxifen antiestrogens. A comparison of the activity, pharmacokinetics, and metabolic activation of the cis and trans isomers of tamoxifen. J Steroid Biochem 16:1-13.
34. Rutqvist LE and Mattsson A (1993) Cardiac and thromboembolic morbidity among postmenopausal women with early-stage breast cancer in a randomized trial of adjuvant tamoxifen. The Stockholm Breast Cancer Study Group. J Natl Cancer Inst 85:1398-1406.
35. Shani J, Gazit A, Livshitz T, and Biran S (1985) Synthesis and receptor-binding affinity of fluorotamoxifen, a possible estrogen-receptor imaging agent. J Med Chem 28:1504-1511.
36. Sun D, Chen G, Dellinger RW, Duncan K, Fang JL, and Lazarus P (2006) Characterization of tamoxifen and 4-hydroxytamoxifen glucuronidation by human UGT1A4 variants. Breast Cancer Res 8:R50.
37. van Leeuwen FE, Benraadt J, Coebergh JW, Kiemeney LA, Gimbrere CH, Otter R, Schouten LJ, Damhuis RA, Bontenbal M, Diepenhorst FW, et al. (1994) Risk of endometrial cancer after tamoxifen treatment of breast cancer. Lancet 343:448-452.
38. Wiener D, Doerge DR, Fang JL, Upadhyaya P, and Lazarus P (2004a) Characterization of N-glucuronidation of the lung carcinogen 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanol (NNAL) in human liver: importance of UDP-glucuronosyltransferase 1A4. Drug Metab Dispos 32:72-79.
39. Wiener D, Fang JL, Dossett N, and Lazarus P (2004b) Correlation between UDP-glucuronosyltransferase genotypes and 4-(methylnitrosamino)-1-(3-pyridyl)-1- butanone glucuronidation phenotype in human liver microsomes. Cancer Res 64:1190-1196.